Here’s a number that should make every state budget office sit up straight. Tennessee restricted major hemp product categories in July. The state had projected roughly $9.4 million in hemp sales-tax collections for that month. Actual collections: about $425,000. That’s a miss of more than 90 percent, and if the pace holds, the annual hole could top $110 million.

For years, cannabis debates lived in the morality department. Should weed be legal, is hemp a loophole, do people belong in jail for it. Those questions still exist, but this weekend’s news lives somewhere politicians pay much closer attention: the financial statements. Michigan’s Republican nominee for governor is saying the state overtaxed its own legal market. South Dakota regulators are begging Washington for an instruction manual on rescheduling. And nearly 900 Missourians are chasing 77 licenses in a program still learning that a license and a viable business are two very different things.

None of this is really about cannabis culture. It’s about capital allocation, tax policy, regulatory certainty, and whether government can actually run the market it created. An industry becomes hard to prohibit once prohibition has budget consequences, and hard to overtax once legal businesses start closing. Cannabis spent years demanding legalization. Now it’s forcing a much less ideological question: can you run the thing you built? Let me walk you through it.

Missouri got nearly 900 applications for 77 licenses, and the lottery is the easy part.

Missouri’s social-equity experiment is entering its final round, and demand is enormous. State regulators received close to 900 applications for the third and final round of marijuana microbusiness licenses, with just 77 available and the Missouri Lottery drawing winners September 9. The program came out of the 2022 voter-approved legalization amendment, built to give smaller and historically excluded entrepreneurs a path into cannabis without needing multistate-operator scale.

On paper, simple. In reality, messy. The first two rounds produced ownership disputes, compliance problems, and multiple license revocations tied to arrangements regulators concluded violated the majority-ownership requirements. So the state tightened up, reviewing ownership structures before issuing licenses instead of discovering shell games afterward, communicating directly with majority owners instead of their consultants, and requiring more compliance education.

That sounds procedural. It goes straight at social equity’s biggest unsolved problem: who actually owns the business? Cannabis licenses can be enormously valuable, and a qualifying applicant may check every statutory box while lacking the millions needed to open. Enter the capital partner, offering funding, expertise, property, and buildout, in exchange for control, economics, and management rights, sometimes so much control that the “majority owner” exists mostly on paper.

Banning exploitative deals doesn’t solve the capital gap. It just means the qualifying owner keeps control of a business that still can’t afford to open.

The stat that matters most: as of August 18, Missouri had 21 operating microbusinesses, five dispensaries and 16 wholesalers, with another 46 licenses active but not yet approved to operate. One early licensee, Jimi Poe, said opening took roughly two years instead of the six months he expected, and when he finally opened, his dispensary carried just nine strains because the microbusiness supply chain was so thin. That’s why these programs should be measured by operating outcomes, licenses opened, capital raised, businesses still majority-controlled, jobs, revenue, three-year survival. Anything less confuses regulatory permission with entrepreneurship.

The bottom line: Nearly 900 applicants prove the demand is real. But social equity doesn’t succeed when someone wins a license. It succeeds when that person still owns and operates a viable company years later.

Tennessee’s hemp ban may have blown a $110 million hole in the budget.

Tennessee wanted less hemp THC. It’s getting a lot less tax revenue too. The state began enforcing restrictions in July that banned major cannabinoid categories, including smokable hemp and THCA products that industry groups say made up as much as 75 percent of the market. Then the first month of tax data landed: $425,000 collected against a $9.4 million projection, a miss of more than 90 percent. Annualized, the gap could exceed $110 million. And this was already a shrinking number, since the state had cut hemp projections by $55 million the prior year and still finished about $55.8 million under.

Fair caveats first: one month doesn’t make a fiscal year, consumer behavior can shift, compliant products could gain share, collections could recover. But the early data illustrates something policymakers chronically underestimate.

When government bans a legal product category, it isn’t just changing criminal or health policy. It’s changing a tax base. And tax bases don’t ask permission before they leave.

Democratic lawmakers are already weaponizing the numbers, with Rep. Aftyn Behn and Sen. Heidi Campbell pushing their “pot for potholes” plan, legal adult-use cannabis with a 15 percent tax pointed at the state’s road backlog. Whether voters want that is a separate question. The more interesting one is: where did the hemp consumer go? If they quit entirely, the policy cut both consumption and revenue. If they moved to untaxed illegal marijuana, the state lost the money and pushed customers outside the regulated system. If they shifted to other legal products, the taxes may resurface elsewhere. That substitution data decides whether the crackdown actually worked. And don’t miss the private-sector shadow of these numbers, because a 90-percent sales collapse means retailers losing revenue, which means layoffs, closures, lease defaults, and loan stress. The government just feels the same shock later, through the treasury.

The bottom line: Prohibition now comes with a measurable price tag. A state can pull a legal product off shelves, but it can’t collect sales tax from a transaction that moved underground.

South Dakota says rescheduling arrived without an instruction manual.

Federal medical-marijuana rescheduling was supposed to create clarity. South Dakota says it created a new category of questions. State medical-cannabis administrator Whitney Brunner told lawmakers that since medical marijuana moved to Schedule III in April, Washington has requested information from the state but provided remarkably little implementation guidance. Her summary: officials still have more questions than answers.

That matters because the benefits at stake are enormous. Schedule III should free medical operators from Section 280E and improve banking access, and for a cannabis CFO those changes ripple through effective tax rates, free cash flow, debt coverage, valuation, and expansion economics. But “should help” isn’t a phrase a bank can underwrite.

A lender needs the details. Does every state medical operator qualify automatically? Is DEA registration required? What inspections? How do you separate qualifying Schedule III revenue from activity that’s still federally prohibited? “Congratulations” is not an operating manual.

Some businesses are pushing ahead anyway. Kittrick Jeffries, who chairs the state’s industry association and owns Puffy’s Dispensary, says multiple member businesses are already going through DEA inspection and licensing. That’s encouraging and alarming at once, encouraging because operators are preparing for federal integration, alarming because they’re spending compliance money before anyone knows the final requirements. Meanwhile South Dakota’s own program is reforming after admitting its inspections were inconsistent, adding training, supervision changes, formal appeals, and possibly lighter penalties for minor first offenses. One operator said a $3,000 penalty for two clerical errors forced him to postpone other spending, which connects the whole story: compliance costs consume capital, and ambiguous compliance consumes even more. You can budget for a clear inspection requirement. You can’t budget for a mystery.

The bottom line: Schedule III may materially improve medical-cannabis economics, but financial normalization takes more than changing one line of the Controlled Substances Act. Banks, businesses, and states need an operating manual, not another headline.

Michigan’s GOP nominee wants lower weed taxes and tighter hemp rules, and that combo is the future.

Michigan’s Republican nominee for governor, John James, has a cannabis platform that would’ve sounded bizarre a few years ago. He wants to repeal or sharply cut the state’s new 24 percent wholesale cannabis tax, while restricting intoxicating hemp products sold outside the licensed marijuana market. And notably, he’s not running against legalization at all, he explicitly says voters approved the 2018 market and government should respect that. His argument is that Michigan is undermining its own legal system through excessive taxation and lopsided competition.

The math backs him up. The 24 percent wholesale levy stacks on top of a 10 percent excise tax and 6 percent sales tax, and the cumulative burden pushes legal prices up while illegal sellers pay nothing. The state projected roughly $420 million from the tax for roads, Republican lawmakers have already filed repeal legislation, and companies are challenging it in court. Now it’s a governor’s race issue.

Cannabis-tax relief isn’t being framed as a progressive legalization cause anymore. It’s a small-business, free-market argument: tax the legal operator too hard and you hand the illegal one a pricing advantage. That travels across party lines.

His hemp position is the other half of the same worldview. He says delta-8, THCA, and synthetic cannabinoids shouldn’t sell through gas stations and smoke shops without the age limits, testing, and labeling that licensed marijuana faces. That’s regulatory parity, if it intoxicates like cannabis, regulate it like cannabis. And that concept is rapidly becoming the political center: not prohibition, not anything-goes hemp, but regulated marijuana, regulated intoxicating cannabinoids, real enforcement against illegal sellers, and lower unnecessary costs for rule-followers. Licensed operators love it. Independent hemp businesses see an attempt to force them into a far more expensive channel. Both readings have merit, and the long-term question is whether product risk or plant definition ends up determining regulation. Michigan suggests risk is winning.

The bottom line: Pro-cannabis-business no longer means pro-every-cannabinoid. The emerging center is lower taxes for licensed operators, stricter standards for intoxicating hemp, and tougher enforcement against everyone outside the system.

Iowa is opening medical cannabis to out-of-state patients, starting with Nebraskans.

Iowa’s medical program is starting to cross state lines. Regulators filed proposed rules removing the residency requirement for qualified patients, following legislation Governor Kim Reynolds signed in June, and restoring reduced registration fees for veterans. The obvious beneficiaries are Nebraskans, since regulators specifically note Nebraska is the only neighboring state without an operational medical or adult-use program. A Nebraska patient could get certified by an Iowa provider and register in Iowa’s program.

Small regulatory change, potentially large implications. Cannabis policy has always been chained to geography, and the absurdity is easy to state.

A medical patient in one state can legally access cannabis. A patient with the identical diagnosis fifteen miles away cannot. The medical need doesn’t change at the border. Only the law does.

Iowa is starting to weaken that distinction, and the same legislation doubled its authorized dispensaries from five to ten to fix geographic access complaints. The program reports 17,741 patients and 524 caregivers, and regulators don’t expect a massive influx, partly because Iowa’s program stays genuinely restrictive: a 4.5-gram THC purchase limit over 90 days for most patients, with smoking and flower prohibited. So this isn’t cannabis tourism, it’s a controlled medical pathway for people with no functioning program at home. For dispensaries near the border, though, the potential service area just changed, and lenders evaluating those businesses should assess patient counts beyond state population alone, because cross-border medical access reshapes trade areas the same way neighboring adult-use markets reshape recreational retail. And the veteran fee fix, restoring a $25 application fee instead of $100 after the language got accidentally deleted in a red-tape review, is small but worth doing. Cannabis regulation has plenty of hard questions. Un-botching a $75 mistake for veterans isn’t one of them.

The bottom line: Iowa is starting to treat medical cannabis like healthcare instead of a residency privilege. A diagnosis doesn’t change when you cross a state line, and programs are slowly beginning to admit it.

Texas hemp operators say the state destroyed jobs without ever changing the law.

Texas’s hemp crackdown is facing another federal lawsuit. Four retailers are challenging the Department of State Health Services, arguing regulators exceeded their authority by classifying broad categories of hemp-derived THC products as illegal, effectively changing policy through executive interpretation rather than legislation. They’re seeking immediate relief and making dramatic economic claims, tens of thousands of job losses, collapsed sales, billions in damage. Important flag: those figures are the plaintiffs’ claims, not judicial findings, and should be read that way.

But the underlying legal issue matters regardless of the final numbers. Businesses built an entire retail ecosystem around their understanding of the 2018 Farm Bill and Texas hemp law, stores, leases, inventory, employees, brands, and then regulators concluded multiple compounds belong in prohibited categories.

This is the scenario lenders fear most. The borrower didn’t become incompetent, demand didn’t vanish, the location didn’t decay, nobody committed fraud. The rules changed. Regulatory risk destroyed credit quality without any conventional deterioration in the business.

That should reshape how banks analyze cannabinoid companies: break revenue down by product category, ask which cannabinoid generates the margin, what percentage rides on disputed legal interpretations, what revenue looks like if one category disappears, how much inventory becomes unsellable, whether the lease and debt survive. Those questions belong in underwriting now. The lawsuit also alleges Texas’s interpretation conveniently benefits the state’s medical-marijuana system by eliminating competing hemp products, again an allegation, not a finding, though removing one channel obviously strengthens the remaining ones. And it all circles back to transition periods. Even if Texas ultimately has the authority, inventory bought under one legal interpretation doesn’t magically vanish, and neither does the debt, payroll, or rent attached to it. If a state believes a product is risky enough to prohibit, the policy analysis should include the cost of shutting the legal market down and what the consumer does afterward.

The bottom line: Texas is a national test of how much regulatory instability cannabis businesses are expected to absorb. A market can’t attract normal capital if the legality of its core inventory changes faster than the loan that financed it.

The DEA is fixing a 2,470-page transcript, and that boring work might protect 280E relief.

Federal rescheduling has reached its least glamorous stage: correcting the record. DEA Chief Administrative Law Judge Derek Julius ordered dozens of changes to the official rescheduling hearing transcript, which runs roughly 2,470 pages, with a corrected version due August 26. Many fixes are names and transcription errors. Some change the meaning of testimony in more material ways.

Here’s why the cleanup matters more than it looks. Administrative decisions are built on the record, and the judge’s recommendation has to rest on the testimony, exhibits, and arguments developed in the proceeding. A sloppy record hands opponents more angles to challenge the outcome.

For an industry impatient for rescheduling, the procedural crawl feels maddening. But a fast rule that gets overturned is worth less than a slow rule built on a defensible record. In cannabis, the most valuable paperwork is the paperwork that keeps 280E relief from getting reversed.

Meanwhile, the substance of DEA’s position remains remarkable on its own. The agency is defending the move to Schedule III, arguing marijuana no longer satisfies Schedule I’s requirements, pointing to widespread medical use and a lower abuse profile than the most restricted drugs. Federal regulators once said cannabis had no accepted medical use. The government’s own record now includes millions of patients and tens of thousands of practitioners. The law is catching up to reality. For the industry, the headline stays the same, a broader Schedule III move could pull marijuana out of 280E’s reach, and a company that looks marginal under 280E can look dramatically healthier once ordinary deductions return, better cash flow, better debt coverage, higher enterprise value. But banks shouldn’t underwrite as if the most favorable outcome is guaranteed. Run the scenarios: current treatment, Schedule III, delayed implementation, litigation. Cannabis finance still requires multiple cases.

The bottom line: The transcript cleanup looks painfully bureaucratic. It may be exactly what durable reform requires, because the biggest tax change in industry history is only valuable if it survives the appeals.

You can be legal enough to buy medical cannabis and illegal enough to go back to jail for it.

Cannabis legalization has produced a strange category of American: someone following one law while violating another. A patient has a qualifying condition, a physician authorizes cannabis, the state issues a card, the patient buys a regulated product from a licensed dispensary. Then their probation conditions say no marijuana. A Reason Foundation opinion piece in Marijuana Moment highlights how common that trap remains for people under supervision.

The scale is bigger than most people realize. Nearly four million Americans are on probation or parole, and some state systems still prohibit marijuana even when the person could legally participate in a medical program. A positive drug test becomes a technical violation, which can trigger sanctions or reincarceration. The piece cites estimates that states spend billions reincarcerating people for technical violations like missed appointments and positive tests, though it concedes the data doesn’t isolate how many involve marijuana specifically. It’s an opinion article, so read the recommendations as advocacy. But the contradiction it identifies is real.

Medical marijuana laws were layered on top of older systems, not swapped in for them. Probation, employment, housing, licensing, firearms, family court, immigration, all coded for prohibition. Call it legalization debt: the headline law changed, and everything downstream still runs the old software.

Federal rescheduling makes the contradiction harder to defend, because if the federal government recognizes accepted medical use, states eventually have to explain why a supervised person taking physician-authorized cannabis is automatically treated differently from someone on any other medication. That doesn’t mean unrestricted access for everyone under supervision, a judge may have individualized safety reasons for conditions. But individualized restriction and blanket prohibition are different things. And the economics are quietly relevant too, since every collateral consequence, employment testing, housing rules, probation conditions, shrinks the pool of people willing or able to participate in legal markets.

The bottom line: Legalization isn’t complete when the dispensary opens. It’s complete when the rest of government stops punishing people for activity the state itself authorized. The next reforms will involve cleaning prohibition out of laws that don’t look like cannabis laws at all.

Closing Thoughts

For a long time, bad cannabis policy had invisible economic consequences. Ban marijuana, people bought it illegally anyway, government never collected the taxes to begin with, banks stayed away, and there wasn’t much regulated activity to destroy. That era is over.

Tennessee proves it beautifully. The state restricted a large legal product category, and one month later, the budget noticed. Not activists, not dispensary owners. The budget. That’s how cannabis becomes politically durable, not because every politician suddenly likes weed, but because prohibition starts creating line items: lost revenue, lost jobs, empty retail space, stressed loans. Then government has to evaluate policy like economics instead of ideology. Michigan is running the same calculation from the other direction, with a Republican nominee arguing the regulated market got too expensive, cut the tax, enforce against illegal sellers, and pull intoxicating hemp into a comparable framework. That’s a very different conservative cannabis position than a decade ago.

Missouri exposes the maturation problem inside social equity. Everyone loves announcing licenses. Almost nobody wants to discuss how much capital it takes to turn paper into a functioning dispensary, and if that capital is missing, the license isn’t wealth, it’s an expensive obligation. Missouri’s new ownership rules rightly target predatory arrangements, but the harder problem remains: how do you get qualifying owners capital without handing away control? South Dakota shows the opposite end, where a genuinely good federal reform arrived without an operating manual, and businesses are spending compliance money on guesswork. Iowa offers the rare story of government just removing friction, since a state border doesn’t change a diagnosis. And Texas is the warning that capital requires confidence the rules will outlive the investment, because when the legality of core inventory can flip every six months, that risk gets priced somewhere, higher rates, lower valuations, less investment, and eventually the consumer pays.

The contradictions in today’s edition, one cannabinoid regulated like marijuana and another like hemp, one state banking on hemp taxes while another erases the market, patients legal enough to buy medicine but not legal enough to consume it, were tolerable when cannabis was small. Cannabis isn’t small anymore. The industry is now big enough that bad regulation leaves receipts, and once government starts receiving those receipts, in tax shortfalls, lawsuits, and bankrupt businesses, the debate changes permanently. It stops being “do we like marijuana?” and becomes “which system actually works?”

That’s what this newsletter is for.

What’s the biggest regulatory challenge your operation is facing right now? Hit reply, I read every response and it shapes what I cover next week.

If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.

Subscribe now

Here’s a genuinely strange question for a Sunday morning: what even is marijuana anymore?

In Hawaii, people were buying hemp-derived THC at regular stores until this week, when the shelves went empty over a testing fight. In North Carolina, hemp is legal and marijuana isn’t, they smell identical, and the state Supreme Court just said that smell can still help justify a police search. Cross a few borders and it gets weirder. Massachusetts voters will decide whether to tear down recreational sales nearly a decade after legalizing. Ohioans can legally buy weed at home but face cheaper product across the Michigan line, which Ohio has made it illegal to bring back. And Texas is banning hemp THC products while candidates argue about whether that just hands the customer to the illicit market.

Welcome to American cannabis policy in 2026. The plant isn’t the confusing part anymore. The rules are. And that’s becoming a serious business problem, because an operator can follow one state’s law and still hit federal risk, a consumer can buy legally on one side of a border and break the law crossing it, and a lender can finance a legal company whose inventory gets banned months later. The industry spent decades demanding legalization. What it needs now might be more important: clarity. Capital can price risk. What it can’t stand is not knowing which rule applies tomorrow. Let me walk you through it.

Hawaii’s hemp crackdown isn’t really hemp vs. marijuana. It’s about parity.

Hawaii officials are defending a crackdown that’s already emptied store shelves. Until recently, adults could walk into ordinary retailers and buy hemp-derived THC without touching the state’s tightly regulated medical marijuana system. Now a lot of that is gone. The Department of Health says it comes down to regulation and testing, since licensed dispensaries operate under heavy requirements while hemp products sold through regular stores didn’t face comparable scrutiny. The industry sees it differently, and a federal lawsuit argues Hawaii is effectively criminalizing hemp that Congress legalized and interfering with interstate commerce.

Underneath the legal fight sits a genuinely interesting commercial question.

Why should two products that produce basically the same effect operate under completely different economic systems? One needs a cannabis license, security, seed-to-sale tracking, and heavy compliance. The other historically sold under a much lighter framework.

That regulatory arbitrage built most of the modern hemp THC industry. Licensed cannabis businesses understandably resent it. Hemp businesses understandably say they built companies around laws the government itself wrote. Hawaii is now trying to close that gap, and here’s where it gets interesting for investors: the future of cannabinoids probably doesn’t belong to either extreme. The current setup, where chemically similar intoxicating products face wildly different rules based on legal definitions, is hard to defend forever. But just deleting one side of the market creates a new problem, because the consumers still exist. Remove hemp THC from regular stores while keeping medical access limited, and some people get medical cards, some stop buying, and some walk straight into the illicit market. That last group is the whole ballgame, because regulation only works when the legal system is attractive enough to actually capture demand. The better long-term answer is probably parity, testing, age limits, labeling, potency standards, real rules, then let the consumer choose. And there’s a wrinkle that makes this even messier: the federal hemp definition is set to tighten later this year anyway, which could make parts of today’s Hawaii lawsuit commercially irrelevant.

The bottom line: Hawaii’s fight isn’t hemp versus marijuana, it’s about regulatory parity. If two intoxicating products chase the same customer, policymakers eventually have to explain why one needs a heavily regulated license and the other doesn’t.

North Carolina legalized something police can’t tell apart from the illegal version by smell.

North Carolina has created one of the stranger side effects of hemp legalization: something can smell exactly like contraband without being contraband. The state Supreme Court upheld another conviction from a vehicle search where cannabis odor helped establish probable cause, the third time this year the court has upheld arrests tied to smell. It says odor can remain one factor within the broader “totality of the circumstances.”

The problem is obvious. North Carolina legalized smokable hemp, and legal hemp flower and illegal marijuana look and smell essentially identical. As a defense attorney put it, people doing something perfectly lawful could end up paying for legalization with weaker Fourth Amendment protection.

For decades, the smell of cannabis told an officer one thing: probably illegal marijuana. Legal hemp destroyed that certainty. The smell stayed the same. The inference behind it fell apart.

And policing doctrine hasn’t caught up. The court hasn’t said odor alone permits every search, and earlier cases leaned on extra factors like masking smells and suspicious behavior. But partial legalization creates this weird in-between period where the exact sensory cue associated with a crime is now also produced by a legal product. Think about it this way: if non-alcoholic beer smelled precisely like an illegal substance, would smelling it tell an officer what was actually in the bottle? That’s the cannabis problem. And it ripples further than most lawmakers consider, since legalization quietly changes agriculture, retail, banking, policing, probable-cause doctrine, drug testing, even police dogs trained to alert on marijuana. For hemp retailers, this matters commercially, because customers who buy legal flower may assume that legality shields them from marijuana-related scrutiny, and North Carolina shows that assumption can be dead wrong.

The bottom line: North Carolina legalized something police can’t reliably distinguish by smell from something illegal. That’s not just a cannabis problem, it’s a legal-system design problem. If lawful conduct smells exactly like criminal conduct, you eventually need better evidence than a nose.

Share Hypotenews

Legalization is creating real farm jobs, and now there’s data to prove it.

For years, supporters promised legalization would create jobs. Now researchers are actually measuring them. A Texas Tech analysis found states that legalized marijuana saw roughly a 9% bump in agricultural employment compared to modeled outcomes without legalization, using Bureau of Labor Statistics data from 1990 through 2024. Notably, ag wages didn’t rise significantly alongside the jobs, and researchers found no statistically significant change in overall employment or economy-wide wages.

That nuance is important, and I want to be honest about it. Legalization didn’t magically transform entire state economies. But it did create measurable demand for agricultural labor, and politically that’s gold.

Jobs are much harder to dismiss than projected market valuations. Somebody gets hired. Somebody gets a paycheck. A facility buys equipment, an HVAC contractor gets work, a warehouse gets leased. Cannabis becomes part of an ordinary economic ecosystem.

The broader legal sector supported around 412,500 direct U.S. jobs in early 2026, but this study is more politically interesting precisely because it isolates agriculture, and a lot of states weighing reform have rural communities hunting for new opportunity. Now, cannabis can’t replace every declining farm sector, and nobody should pretend every cultivation license becomes a family farm, since modern cultivation can be highly industrialized. But it’s a new legal crop, and new crops need labor. There’s a real-estate angle too, since cultivation often repurposes warehouses and industrial properties with otherwise limited demand, generating secondary activity around electricity, water, security, and processing. For banks, measurable employment strengthens the case to treat cannabis like other specialized agricultural industries, because a cultivation borrower isn’t mysterious, it has production costs, inventory, labor, wholesale customers, crop risk, and equipment. The regulatory exposure is still unusually high. The underlying economics are increasingly conventional.

The bottom line: Legalization’s economic argument is becoming measurable instead of theoretical. The next challenge is making sure those jobs turn into durable local value, not just bigger cultivation footprints.

Share

Massachusetts is about to test whether legalization can be un-installed.

The cannabis movement knows how to campaign for legalization. Massachusetts is about to find out if it knows how to campaign against repeal. A November ballot initiative would dismantle regulated recreational sales and eliminate home cultivation while keeping possession legal and preserving the medical program. The Marijuana Policy Project is warning that a repeal win, or even a nervously close defense, could inspire copycat campaigns in other mature states and spook investors.

That makes Massachusetts a national test. For years, cannabis politics only moved one direction, Colorado, Washington, Oregon, California, and on down the line, and the assumption became that once a state crossed the bridge, nobody walked back. That assumption is now on trial. And the proposed model is genuinely bizarre: adults could still legally possess cannabis, but the regulated system supplying it would vanish.

Where exactly are consumers supposed to get the cannabis they’re legally allowed to possess? Recreational demand doesn’t disappear because storefronts close. It just goes looking for a new supplier, and the obvious candidate is the illicit market.

That actually hands legalization advocates a stronger argument than personal freedom. They can compare two supply systems side by side: one pays taxes, one doesn’t. One tests products, one doesn’t. One can lose its license for selling to minors, the other has no license to lose. One creates documented jobs and can run recalls, the other can’t. But the industry should not get cocky here, because voters may have real frustrations with commercialization, advertising, store density, potency, odor, impaired driving, corporate consolidation. If operators wave those away because “legalization already won,” they risk getting politically disconnected from their own customers and neighbors. Normal industries defend their social license constantly. Banks do it, alcohol does it, casinos do it. Cannabis will have to as well, and its best defense is simply performance: create jobs, pay taxes, keep product away from kids, and make the legal market visibly better than what it replaced.

The bottom line: The legalization movement’s next campaign may be defending legalization itself. Winning a ballot initiative gives an industry permission to operate. It does not grant permanent political immunity.

Texas cannabis politics has become a fight over who gets the customer.

Texas Democratic Senate candidate James Talarico is sharpening the argument that prohibition isn’t just drug policy, it’s market policy. He’s accused Republican opponent and AG Ken Paxton of backing cannabis restrictions in ways that benefit contributors tied to alcohol and tobacco. Paxton didn’t respond to the outlet seeking comment, and I’ll flag clearly that the motive claim is a political allegation, not an established finding. But the economics underneath are worth examining.

Texas restored restrictions on delta-8, delta-10, and other cannabinoids, so products people used to buy from ordinary registered businesses may now fall into Schedule I under state law. And Talarico’s question is simple: what happens to the customer?

The state can eliminate a legal product category. It cannot order consumer demand to disappear. Some switch to compliant products, some quit, some move to alcohol, and some buy illegally. The policy doesn’t erase the market. It reallocates it.

That’s especially relevant now that cannabis and alcohol increasingly compete for the same occasions, THC drinks against beer, edibles against a nightcap. Alcohol companies have noticed, and some are trying to enter THC distribution themselves. What makes Talarico’s framing potentially powerful is that he isn’t asking conservative Texans to embrace cannabis culture. He’s asking why government should decide which industry gets the customer, which is an argument that lands with free-market conservatives, small businesses, libertarians, and voters skeptical of corporate influence. The Paxton allegation still needs evidence to be more than campaign rhetoric, since contributions alone don’t prove corruption. But the deeper shift is real: reform arguments increasingly run on economics, competition, jobs, small business, consumer choice, illicit-market displacement, which may prove far more durable than endlessly debating whether weed is “good” or “bad.” Consumers already settled that individually. The market already exists. Government is just deciding which version gets to operate.

The bottom line: Prohibition doesn’t necessarily eliminate demand. It reallocates revenue. The fight is increasingly about who receives it, the regulated business, an incumbent competitor, or the underground seller.

Ohio legalized cannabis. Michigan still has the better deal.

Ohio has discovered one of the less glamorous laws of legalization: consumers compare prices. The median ounce in Ohio runs about $147.35 versus $99 in Michigan, and a median eighth is about $35 in Ohio against $20 in Michigan. That gap matters because Ohio consumers had years to build shopping habits in Michigan before their own market even opened, since Ohio adult-use sales started in August 2024 and Michigan’s began years earlier, giving Michigan a deeper cultivation base and serious price compression. Ohio’s response to cross-border buying was to make it illegal to bring legally purchased out-of-state marijuana back home.

Legally straightforward. Economically fascinating.

Ohio has basically told consumers: cannabis is legal, but buying cheaper legal cannabis somewhere else and driving it home isn’t. The rule does nothing about the underlying price gap. It just threatens the customer for noticing it.

This is one of the lessons legal markets teach over and over. Government keeps modeling demand as if legalization creates a captive customer. It doesn’t. The consumer always has alternatives, another legal state, the illicit market, home cultivation, hemp products, or just buying less. Which means taxes, licensing limits, and supply constraints all shape how much of the market the legal system actually captures. Ohio compounds it with heavy local restrictions, since more than 160 municipalities and townships maintain dispensary moratoriums, and fewer stores means less convenience, which stacked on higher prices hands Michigan an obvious edge near the border. For lenders and investors, the lesson is concrete: don’t evaluate a dispensary just by population within five miles. Look at competing stores, state borders, local bans, pricing, travel patterns, and illicit-market strength. Cannabis retail is becoming ordinary retail, where location and price win and regulatory permission alone doesn’t.

The bottom line: Legalization doesn’t guarantee customer loyalty. People don’t buy regulatory frameworks, they buy products. If another market sells the same thing much cheaper, the border is a speed bump, not a moat.

The DEA’s HHC fight shows why “hemp-derived” is losing its magic.

The DEA is defending its position that synthetically produced HHC is already Schedule I. It gave the compound its own tracking code earlier this year, hemp businesses challenged it, and the agency’s response is essentially that the companies are attacking an administrative change that didn’t alter the drug’s legal status, since HHC was already Schedule I when made synthetically and the code just makes tracking easier.

Sounds like an obscure procedural spat. It may define the next generation of cannabinoid regulation. For years the hemp industry’s most powerful phrase was “derived from hemp.” The 2018 Farm Bill made hemp lawful, and entrepreneurs figured out they could extract legal CBD and chemically convert it into other intoxicating cannabinoids. The source was hemp, but the finished molecule could behave completely differently.

The DEA is increasingly saying source isn’t the only question. Process matters. Was it naturally extracted? Was another cannabinoid converted into it? Was it synthesized? That single distinction could separate the legal cannabinoids from the illegal ones.

For banks, this rewrites due diligence entirely. “Does the customer sell hemp?” stops being a useful compliance question. The institution may need to understand individual SKUs, cannabinoid composition, manufacturing method, lab testing, state legality, federal interpretation, and distribution, which is closer to pharmaceutical or specialty-chemical diligence than ordinary agricultural lending. It’s also a survival test for the companies themselves. Businesses built around ambiguity thrived after 2018, but ambiguity is hard to finance, hard to insure, hard to scale, and eventually regulators close it. The strongest players will be the ones that can operate once lawmakers write explicit rules, which probably means fewer exotic converted cannabinoids and more standardized products, national testing standards, age limits, and clear lines between natural and synthetic compounds. That shrinks parts of today’s market. It could also make the surviving market far more bankable.

The bottom line: The next regulatory question isn’t “did it come from hemp?” It’s “how did you make it?” That distinction could wipe out some business models while making others a lot more legitimate.

Texas critics warn prohibition could make the hemp market less safe, not safer.

A Marijuana Moment op-ed from criminal-justice advocate Michael A. Davis makes a provocative case about Texas’s crackdown: the state may be removing the businesses it can regulate while leaving the ones it can’t. Davis doesn’t claim the hemp market was perfect, and he acknowledges real concerns about youth-oriented packaging, inconsistent testing, and questionable products. His point is that those problems called for stronger regulation, not a return to prohibition.

Texas already had pieces of a regulatory framework, age restrictions, ID requirements, testing, labeling, inspections, all of which could theoretically have been strengthened. Instead the state restored restrictions that pulled products out of ordinary legal commerce. And the business logic here is worth sitting with regardless of how you feel about hemp.

A licensed retailer has assets the government can threaten, a license, a lease, a bank account, inventory, a reputation. An illicit seller already operates outside all of it. You can’t revoke a license the dealer never had.

If a licensed store sells to minors, regulators can penalize it. If testing fails, inventory gets recalled. If labels are fraudulent, the state knows exactly where to find the company. None of that leverage exists over the underground seller. This doesn’t mean every intoxicating cannabinoid belongs on a convenience-store shelf, and some compounds may deserve much stricter control. But risk-based regulation and prohibition are different strategies, a 5mg beverage may need one framework, a converted high-potency cannabinoid another, a CBD tincture another. The catch is administrative complexity, because real regulation means government has to understand the products, test them, classify them, license sellers, and monitor compliance. Prohibition is easier, you just say no. The open question is whether easier produces better outcomes, and Texas is about to generate real evidence. If consumption falls sharply, the crackdown’s supporters have a case. If consumers just migrate to illicit marijuana or underground cannabinoids, critics will argue the policy moved commerce without reducing demand.

The bottom line: Texas is running a live experiment, does prohibition eliminate a cannabinoid market, or just remove the regulated seller from it? The answer will matter far beyond Texas.

Sunday closing

Twenty years ago, cannabis law was harsh but simple. Marijuana was illegal, full stop.

Today, a product can be legal because it came from hemp, unless the manufacturing process changes the answer. A consumer can legally buy cannabis, unless they bought it in the wrong legal state. A substance can smell exactly like marijuana but actually be lawful hemp, and police can still use that smell to justify a search. A state can spend a decade building a legal industry, and then voters can be asked whether they want to tear it down. That’s not just legal complexity. It’s economic friction, and every unclear rule carries a cost, lawyers, compliance officers, inventory write-offs, higher financing costs, payment-processing headaches, insurance premiums, delayed investment, and businesses simply deciding the uncertainty isn’t worth it.

That should worry regulators, and here’s the key point: good regulation doesn’t mean weak regulation. Cannabis can absolutely have strict testing, age controls, potency standards, packaging rules, advertising limits, taxes, and serious penalties for violators. But the rules have to be understandable, reasonably durable, and economically sensible for similar products. Hawaii captures the whole challenge, officials are right to ask why consumers should buy untested intoxicating products, and hemp businesses are equally right to ask why the government let an industry develop and then changed the rules after everyone invested. Both problems have the same solution: regulate the product. North Carolina shows a different failure, legalizing hemp without updating the assumptions around cannabis odor, so lawful conduct stays suspicious because the legal system hasn’t caught up. Ohio shows the cost of ignoring economics, because you can legalize, license, and ban interstate transport, but if Michigan sells the same thing cheaper, consumers notice. Markets always notice.

And Massachusetts may be the biggest warning of all: legalization isn’t permanent just because businesses built stores around it. An industry has to keep earning its political legitimacy, create jobs, protect consumers, pay taxes, employ locals, operate responsibly, and give voters a reason to prefer regulated commerce over the alternative. The agricultural jobs study hands the industry exactly that kind of evidence, proof that cannabis isn’t just generating sales but measurable economic activity. Because cannabis doesn’t have to prove people want it anymore. That was settled long ago. The real challenge now is building rules that consumers can understand, businesses can survive, and banks can actually underwrite. America already built a cannabis economy. Now it has to decide whether it wants that economy regulated, or just confused.

That’s what this newsletter is for.

What’s the biggest regulatory challenge your operation is facing right now? Hit reply, I read every response and it shapes what I cover next week.

If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.

Subscribe now

Here’s a snapshot of American cannabis policy in a single 48-hour window. The DEA drew a hard line insisting a synthetic cannabinoid stays Schedule I. Illinois moved the opposite direction, letting adult-use dispensaries serve medical patients at the lower tax rate. Virginia is about to erase a hemp exception on Saturday, giving businesses roughly 40 days to reformulate or eat their inventory, with one owner saying it could bankrupt her. And Houston is sending voters a measure to make marijuana arrests the lowest priority for city police.

Same country. Same plant. Four completely different theories of how to regulate it.

If you’re still picturing cannabis as one big national argument, legal versus illegal, pro versus anti, feds versus states, that frame has stopped being useful. The real fight now is quieter and far more consequential: who regulates which cannabinoid, under what commercial system, at what tax rate, with how much transition time. Those questions sound boring next to “legalize it.” They’re not. They decide who survives. A 5mg THC seltzer treated like alcohol gets national wholesalers and mainstream retail. The same molecule packaged differently faces prohibition. This is what a maturing industry looks like, and the businesses that figure that out first are going to have a massive edge. Let me walk you through it.

The DEA is separating cannabis chemistry from cannabis agriculture, and it changes everything.

The DEA is defending its position that HHC, a cannabinoid made through chemical conversion, is already Schedule I, escalating a legal fight that could shape how federal law treats converted cannabinoids across the board. Back in May, the agency gave HHC its own drug code. Hemp companies challenged it, arguing some HHC products qualify as lawful hemp. The DEA’s clever response: the new code didn’t change anything, because HHC has been Schedule I for decades thanks to its relationship to THC, and the code is just an administrative tracking tool, not a new act of prohibition.

That sounds like dry procedural stuff. Commercially, it’s enormous. The whole post-2018 cannabinoid market is built on products that start as lawful hemp material and then get chemically converted before they hit the shelf. Delta-8 was the famous example. HHC followed. And regulators are increasingly focused not on where a cannabinoid came from, but on how it came to exist.

“Hemp-derived” may be losing its power as a legal defense. The molecule’s origin story matters less than its manufacturing process now, and that’s a completely different question.

That reframes what a banker underwriting one of these companies should even be asking. Not just “is it hemp,” but: what molecule is this, does it occur naturally in cannabis at useful concentrations, does the process convert CBD into the finished compound, what solvents and catalysts get used, what’s the federal legal theory. Those stopped being chemistry questions and became credit questions. And there’s a double bind here, because the DEA also points to the broader November hemp change, when the federal definition tightens sharply unless Congress acts. So even a company that beats the DEA’s interpretation could still get squeezed by Congress. The strongest hemp businesses from here on will be the ones that can survive without leaning on legal ambiguity.

The bottom line: The federal government is starting to distinguish cannabis chemistry from cannabis agriculture. Calling something “hemp-derived” may no longer be enough, and the production method is becoming as important as the plant it came from.

Illinois is blurring the line between medical and rec, on purpose.

Illinois published a new application letting licensed adult-use dispensaries in good standing get a separate authorization to sell medical cannabis, with applications opening September 10. It came out of the broader cannabis law Governor Pritzker signed earlier this year, and stores that get the extra license can serve registered patients at the lower medical tax rate.

This isn’t a simple checkbox, though. Operators pay a $5,000 non-refundable application fee, face another $10,000 in renewal costs, and have to submit ownership, disciplinary, and tax-compliance info. More interesting, they have to explain how they’ll actually prioritize medical patients, including dedicated lines or registers and a consultation area. That detail matters, because legalization tends to quietly strangle medical programs.

Adult-use markets are bigger, busier, and more profitable. Left alone, they turn medical patients into an afterthought inside an industry that was originally built for them.

Illinois is trying to preserve the medical distinction while expanding where patients can shop, which is a genuine win, more locations means less travel and more competition. And the tax gap is real money for someone using cannabis regularly for pain or cancer treatment, because taxes compound fast on recurring purchases. The broader law goes further too, doubling possession limits, expanding expungement, and adding qualifying conditions like endometriosis and uterine fibroids, while also tightening hemp THC rules to match the coming federal 0.4mg framework. That combination is the tell. Illinois isn’t simply “pro-cannabis.” It’s sorting cannabinoids into clearly defined lanes: expand access for licensed marijuana and medical, restrict hemp products outside the favored framework. That may become the dominant state playbook. For operators, the medical opt-in is a new revenue channel but also a real service obligation, since medical patients need staff who actually know the products and reliable access to specific formulations, not just a discount.

The bottom line: Illinois is building one retail network serving different consumer classes under different rules. It makes commercial sense, but if adult-use stores want medical revenue, they need to deliver genuinely medical-level service.

Virginia gave hemp businesses 40 days, and it could bankrupt them.

Virginia is about to become the clearest example of what happens when a regulatory change slams into business debt. Seven hemp companies are asking a federal court to block new restrictions taking effect August 15. The change kills an exception that let certain hemp products carry more than 2mg of THC per package as long as they also had at least 25 times as much CBD. Without it, consumable hemp products generally have to stay under 2mg total THC per package.

The businesses say the economics are brutal. They were formally notified in early July, leaving roughly 40 days to reformulate products, redesign packaging, renegotiate manufacturing, and figure out what to do with inventory that’s about to become unsellable. District Hemp Botanicals founder Barbara Biddle says it could bankrupt her company, which has affected inventory, substantial creditor obligations, has already cut staff, and expects to end a store lease. Virginia officials defend it on consumer-protection grounds, and Attorney General Jay Jones says it creates clearer standards ahead of the state’s developing recreational market.

Here’s the thing: both can be true. Virginia has a legitimate interest in deciding which intoxicating products sell outside its licensed system. And businesses have a legitimate expectation that a dramatic rule change comes with enough transition time that lawful inventory doesn’t turn into an overnight liability. That second issue gets almost no attention in cannabis policymaking, and it should. Picture a company that borrowed $250,000 for inventory, packaging, and a multiyear lease. Every product was legal when purchased. Then the standard changes.

The regulator changes the value of the collateral without changing any of the obligations attached to it. The bank still wants payment. The landlord still wants rent. The inventory is just suddenly worthless.

That’s why transition periods matter, and they’re not favors to industry, they’re basic tools of predictable regulation. Sell-through windows, grandfathering inventory by manufacture date, phasing potency changes gradually. And Virginia’s situation is especially odd because it’s simultaneously building a future adult-use market that may allow products with far more THC than the hemp products it’s banning today. Critics argue that’s inconsistent treatment based on regulatory channel rather than actual risk, and they have a point.

The bottom line: Businesses can survive stricter regulation. What destroys them is regulation without transition. Turning lawful inventory into unsellable inventory in 40 days isn’t just regulating health risk, it’s reallocating financial losses.

Houston isn’t asking voters to like weed. It’s asking them to price prohibition.

Houston’s cannabis initiative is officially going to voters. The City Council put the Houston Freedom Act on the November ballot after organizers turned in nearly 40,000 signatures, and if it passes, misdemeanor marijuana possession becomes the lowest possible enforcement priority for city police.

Important distinction: this does not legalize cannabis. Texas law stays intact, and officers could still seize suspected marijuana with probable cause. But the city would formally steer scarce enforcement resources away from misdemeanor possession toward higher-priority public safety. And that framing might be the single most effective cannabis reform argument in prohibition states.

Don’t ask the voter “do you approve of marijuana?” Ask “should police spend their time on this?” Those are completely different questions, and the second one wins in places the first one loses.

Someone can personally dislike cannabis and still think an officer’s time is better spent on robberies, assaults, or car theft. The initiative leans right into that, talking about resource allocation, reducing discriminatory enforcement, and diversion options like community service. It turns cannabis policy into municipal budgeting: how many officer hours, how much evidence processing, lab testing, prosecutor time, jail capacity. Once you measure enforcement economically, the political math shifts. Texas is especially interesting because state policy is tightening on hemp cannabinoids at the same time, so a Houston voter could be asked to care less about ordinary possession while the state cracks down on products sold openly through hemp channels. That contradiction won’t be easy to explain. And it shows why local reform matters, because normalization often happens city by city, a prosecutor declines cases, police deprioritize, a city builds diversion, until statutory prohibition drifts away from actual enforcement and the pressure moves upward. For businesses, Houston is a signal, since Texas is one of the biggest unrealized adult-use markets in the country.

The bottom line: Houston isn’t asking voters to embrace marijuana. It’s asking them to price prohibition. Once enforcement becomes a resource-allocation decision instead of a morality debate, reform gets much harder to dismiss.

A Republican senator says Trump is “misinformed” about hemp, and the whole fight is scrambled.

The federal hemp fight has gotten so politically tangled that a Republican senator is now publicly criticizing a Republican president’s grasp of the issue. Sen. Ted Budd of North Carolina says Trump has been “misinformed” by White House staff about the consequences of the coming hemp restrictions. Budd led the failed Senate effort to keep the November crackdown on schedule, which got tabled 61 to 32, preserving language that would delay most restrictions to December 11 if the funding measure becomes law. The White House backed the delay. Budd didn’t.

A lot of the disagreement is about CBD. CMS Administrator Dr. Mehmet Oz warned that rushing the restriction could undermine federal healthcare initiatives involving hemp products, while Budd argues policymakers are confusing non-intoxicating CBD with the intoxicating market he wants restricted. And that confusion is exactly the problem.

“Hemp” now describes industrial fiber, CBD tinctures, 5mg beverages, delta-8 gummies, THCA flower, converted cannabinoids, and novel synthetics. Governing all of that with one definition is becoming impossible.

The government wants to solve it through definitions. Industry increasingly wants product-specific rules. Those approaches are colliding. And there’s an irony worth noting: Trump signed the original 2018 Farm Bill that created this market, then signed the legislation with the tighter definition, and his administration is now urging Congress to soften the impact. That’s not necessarily hypocrisy, it may just reflect how radically the industry mutated after 2018. Congress legalized an agricultural category, entrepreneurs turned it into a national cannabinoid consumer market, and regulation never caught up. Here’s the upside for the industry, though: hemp used to be politically vulnerable when one party could tag it as the other party’s issue. Now it cuts across agriculture, healthcare, beverages, small business, and consumer safety. Messier coalitions, but potentially more durable ones.

The bottom line: Hemp is no longer Republican versus Democrat. It’s product versus product, regulator versus regulator, constituency versus constituency. That fragmentation may be exactly what eventually forces Congress to regulate cannabinoids individually instead of with one blunt definition.

Share

North Carolina’s hemp chaos is a warning: you can’t scale chaos.

A Marijuana Moment op-ed from North Carolina hemp operator Chris Karazin makes a point that’ll ring true for basically every regulated cannabis business: you cannot scale chaos. He describes burning enormous time tracking constantly shifting legislation instead of serving customers or planning growth, and argues Congress should learn from North Carolina before designing the next national framework.

The state’s House Bill 328 started narrow, aimed at hemp on school property, then ballooned during the process until it threatened broad categories of existing products. That produced the exact uncertainty operators hate: what inventory do we buy, do we hire, do we sign another lease, should a farmer plant next year’s crop, will this product even be legal when it reaches the shelf. And here’s the nuance politicians keep missing: Karazin isn’t anti-regulation. He supports age limits, testing, labeling, manufacturing standards, enforcement. His objection is unpredictability.

Industry resistance to a rule doesn’t always mean the industry wants no rules. Sometimes it just means they need to know what the rule will be long enough to build a company around it.

This should matter intensely to lenders, because credit runs on predictability. A bank doesn’t need a cannabis borrower operating in a zero-regulation Wild West, quite the opposite, clear rules improve underwriting. The lender wants to know what’s legal, what license is required, what happens on a violation, whether inventory can cross state lines. Regulatory certainty creates measurable risk. Regulatory chaos creates unmeasurable risk, and unmeasurable risk either drives financing costs up or eliminates financing entirely. North Carolina also shows the danger of treating all cannabinoids as identical, when THCO, THCP, THCV, CBD, and low-dose delta-9 have dramatically different pharmacology. One blunt rule is administratively easy and economically irrational.

The bottom line: The hemp industry’s strongest argument is no longer “leave us alone.” It’s “give us strict rules and stop changing them every few months.” Predictable regulation attracts capital. Uncertainty sends it running.

Share Hypotenews

Michigan is discovering you can tax yourself out of the revenue you wanted.

Michigan’s cannabis tax experiment is already drawing a repeal fight. Republican Rep. James DeSana introduced legislation to repeal a recently enacted 24% wholesale marijuana tax, which was meant to fund transportation infrastructure and projected to raise about $420 million. DeSana says revenue is badly underperforming while legal operators get pushed deeper into distress.

The market evidence is hard to ignore. Higher Love Cannabis is suspending operations at five of its nine dispensaries, citing mounting taxes on top of the pressures already hammering Michigan’s market: oversupply, wholesale price compression, thinning margins, a 10% retail excise tax, 6% sales tax, and now the wholesale levy on top.

This is cannabis’s version of the Laffer curve. Governments see a big legal market and assume a higher rate means more revenue. But cannabis consumers have alternatives, and the illicit seller charges no tax at all.

When taxes push legal prices too far above the competing channels, the tax base itself starts shrinking. And businesses react, a dispensary closes, employees lose jobs, wholesale orders vanish, cultivators lose customers, landlords lose tenants, and the state collects zero cannabis tax from that location. This is why cannabis can’t be taxed like a captive industry. Policymakers often treat illicit cannabis as a separate law-enforcement problem, but economically the two are joined, since every dollar added to legal pricing strengthens the illicit seller’s position. The tax also creates financing problems, because lenders underwrite on cash flow, and a margin-compressing levy can push a borrower below debt-service coverage, which hits expansion, equipment, real estate, and hiring. Michigan still sends substantial cannabis revenue to municipalities and tribes, which is exactly why the state should care about operator survival.

The bottom line: The legal market is not a tax ATM. Cannabis taxes only work while the regulated price stays competitive with the unregulated one. Michigan may be discovering governments can tax themselves right out of the revenue they were chasing.

Big Alcohol just publicly asked for the keys to THC drinks.

The transformation of THC beverages into a mainstream category just got impossible to ignore. Major alcohol-industry groups are openly backing bipartisan federal legislation to keep low-dose hemp THC drinks legal and regulate them through an alcohol-style structure. The Wine & Spirits Wholesalers of America and the Beverage Alcohol Merchants Coalition endorsed the Beverage Regulatory Parity Act, introduced by Republican Rep. Beth Van Duyne of Texas and Democratic Rep. Greg Landsman of Ohio.

The message from alcohol distributors is a real shift: properly dosed THC beverages belong in a regulated adult-beverage marketplace. Not a gray area. Not necessarily a dispensary. An adult-beverage marketplace. For years the alcohol-cannabis relationship was framed as pure competition, would people drink less if weed were legal, would beer lose younger drinkers. Those questions remain, but big players are recognizing another option.

If the consumer wants THC drinks, sell THC drinks. That’s what established industries do. They absorb the challenger.

The commercial implications are enormous, because alcohol wholesalers already have the warehouses, delivery routes, retailer relationships, sales teams, compliance systems, age-gated outlets, and national distribution knowledge that cannabis beverage startups simply don’t. So mainstreaming THC drinks could ironically shift a big chunk of cannabis economics toward companies that never thought of themselves as cannabis businesses. The competitive map changes overnight, dispensary brand versus cannabis startup becomes cannabis startup versus national beverage distributor, and that’s a very different fight. The retail landscape expands too: liquor stores, bars, restaurants, hospitality groups, a far larger network than dispensaries alone. And it changes consumer behavior, because people don’t make a deliberate trip to a cannabis store, they just grab a different drink from the same fridge where they used to grab a beer. At that point THC beverage isn’t primarily a cannabis product. It’s an occasion product, dinner, a concert, a barbecue, Friday night, watching the game. That’s how alcohol companies think, and cannabis beverage companies should start thinking the same way.

The bottom line: The alcohol industry isn’t waiting to see whether THC drinks compete with it. It’s positioning to own the distribution. The future beverage winner may not have the best strain story. It may be whoever gets onto the same truck as the beer.

Weekend closing

The strangest thing about today’s edition is how little of it is actually about legalization.

The DEA’s HHC fight is about manufacturing. Illinois is about retail channels. Virginia is about inventory write-downs and transition periods. Houston is about municipal budgets. Michigan is about tax elasticity. The alcohol story is about distribution. Those are all ordinary business problems, and that may be the strongest sign yet that cannabis is becoming an ordinary industry.

For years, a cannabis company could explain almost any problem with two words: federal prohibition. That still matters enormously, but it no longer explains everything. A legal company can now fail because its tax structure is irrational. A hemp company can fail because lawmakers gave it 40 days to dump newly noncompliant inventory. A medical program can wither because patients can’t reach convenient stores. A beverage company can lose because a competitor has better distribution. A lender can lose money because a borrower’s product mix becomes illegal even though the business stays licensed. That’s the next stage. Microeconomics matters now, distribution, working capital, tax elasticity, product classification, credit, and politics in increasingly unpredictable ways.

The alcohol story captures it best. A few years ago cannabis and alcohol were treated as enemies. Today major alcohol wholesalers are effectively saying: if consumers want THC beverages, regulate them properly and let us sell them. That’s how industries actually normalize, not when everyone stops resisting, but when existing economic institutions figure out how to make money from them. Illinois is doing a government version of the same thing, consolidating retail instead of maintaining separate systems forever. Virginia shows what badly managed consolidation looks like. Michigan shows that legalization doesn’t hand government unlimited pricing power, because there’s always another competitor, usually an untaxed one. And Houston asks the most basic question of all: if adults keep using cannabis regardless, how many police resources are we willing to spend proving we object?

The next five years of cannabis policy may be less dramatic than the last fifteen. Fewer historic ballot nights, fewer first-dispensary ribbon cuttings. Instead: tax fights, distribution fights, licensing fights, banking fights, product-definition fights, and lawsuits over transition periods. That sounds less exciting. It’s actually progress, because those are the arguments governments have about industries they expect to stick around. Cannabis spent decades fighting for permission to enter the economy. Now everyone’s fighting over the rules of the economy it entered. This time the winners won’t just be the companies that survive prohibition. They’ll be the ones that understand regulation, capital, and distribution better than everybody else.

That’s what this newsletter is for.

What’s the biggest regulatory challenge your operation is facing right now? Hit reply, I read every response and it shapes what I cover next week.

If this was useful, forward it to someone in the cannabis space or hit the restack button on Substack. It’s how this community grows.

Subscribe now

Wine and spirits wholesalers are now lobbying to keep THC drinks legal, a congressman’s “White House backing” turns out to be shaky, and cannabis is quietly becoming part of cancer care.

Read more

Cannabis voters are souring on Trump’s slow reform, hemp farmers are staring down a November cliff, and the industry just wrote $15 million in checks to find out whose reform actually wins.

Read more

Here’s why that shift matters. Institutions don’t move…

Read more

Cannabis reform isn’t about legalization anymore. It’s about rights, housing, hemp, and who quietly gets priced out of the legal future.

Read more

Look at the spread of fights this week. A state Senate is being pressured to simply allow a vote. The DEA and FDA stood up in a federal hea…

Read more

Read more

The next winners in cannabis won’t be the loudest. They’ll be the most prepared.

Read more

For twenty years, cannabis reform followed a predictable script: legalization campaigns, ballot initiatives, state legislation, public opinion. Win hearts, win votes, win markets.

That script is being torn up.

The biggest cannabis stories this week aren’t about new states legalizing or new markets opening. They’re ab…

Read more

This week, the White House quietly signaled that the crackdown isn’t coming — at least not the version everyone feared.

That single shift tells you almost everything about where cannabis policy is heading in 2026. The fight is…

Read more

Progress and regression are happening simultaneously.

This week, the WNBA removed cannabis from its banned substances list — a genuine cultural milestone. At the same moment, congressional amendments designed to protect hemp-derived THC products were blocked, a lawsuit was filed against federal rescheduling, and Virginia’s governor vetoed a bill that would have finally opened retail sales in a state where cannabis is already technically legal.

That’s the cannabis industry in 2026. Two steps forward, one step sideways, one step into a courtroom.

The operators who thrive in this environment won’t be the ones waiting for clarity to arrive. They’ll be the ones building their businesses to function without it.

Here’s what happened this week — and what I actually think it means.

Share

The WNBA just made a bigger statement than most politicians have.

The WNBA officially removed cannabis from its banned substances list this week, while simultaneously establishing guidelines for player endorsements with cannabis companies.

Let’s be clear about what this actually is: a major professional sports league looked at cannabis and decided it belongs in the same category as alcohol and caffeine, not steroids and amphetamines. That’s not a small thing.

Professional sports leagues have historically been among the last institutions to update their cannabis policies — for obvious reasons, sponsors, federal relationships, image concerns. The fact that the WNBA moved here, and moved decisively, reflects something real about where mainstream America has landed on this issue.

The endorsement piece may end up mattering even more than the policy change. Athletes carry consumer trust in a way that brands spend millions trying to manufacture. Cannabis companies that build authentic relationships with WNBA players now are making a long-term bet that will look smart in five years.

The bottom line: When professional sports leagues start treating cannabis like a normal consumer product, the cultural argument is over. We’re there.

Share Hypotenews

Hemp’s worst week in years — and it’s not over.

Congressional amendments designed to protect hemp-derived THC products — Delta-8, THCA flower, hemp beverages, alternative cannabinoids — were blocked from advancing this week.

I want to be direct about how serious this is. The hemp-derived cannabinoid market has grown into a multi-billion dollar industry operating in a regulatory gray zone that Congress created, largely by accident, with the 2018 Farm Bill. That gray zone is closing.

The arguments on both sides are real. Hemp operators argue they’re driving innovation and expanding consumer access to cannabinoids that help people. Licensed cannabis operators argue they’re competing against businesses that don’t pay their taxes, don’t carry their licensing costs, and don’t play by the same compliance rules. Both are telling the truth.

But here’s what I think actually happens: Congress will pass something restrictive, it will be written poorly, it will disproportionately hurt smaller operators who can’t afford the legal firepower to navigate new requirements, and the big players on both sides will be fine. That’s how these things tend to go.

If you’re in the hemp space and you’ve been hoping this problem goes away on its own — it won’t. The window to build your compliance infrastructure before the rules land is shorter than you think.

The bottom line: The hemp THC fight may be the single most consequential cannabis policy battle of 2026. Treat it that way.

Leave a comment

Virginia is still Virginia.

After Governor Abigail Spanberger vetoed legislation to legalize adult-use retail sales, Virginia lawmakers are now exploring whether they can attach legalization provisions to budget legislation to get around the veto.

I’ve written about Virginia before and my view hasn’t changed: this state is the clearest possible example of the gap between legalizing cannabis and building a cannabis market. Residents can possess it. They can grow it at home. They just can’t buy it from a regulated retailer. That’s not a cannabis policy — it’s a contradiction.

The budget legislation route is creative, and it might work. But it’s also a sign of how politically complicated this has become. When you’re trying to pass cannabis legalization through budget amendments, you’ve moved well past simple policy disagreement into something messier.

The deeper issue is that every state watching Virginia is learning the same lesson: the political coalition that passes legalization is not always the same coalition that builds a functional market. Those are two different fights, requiring two different strategies.

The bottom line: Virginia will get there. But the timeline keeps moving, and the lesson for other states is getting clearer: plan your implementation before you pass your bill, not after.

Someone sued Trump over rescheduling. Here’s why it matters.

A coalition of physicians, substance abuse professionals, and cannabis pharmaceutical interests filed a lawsuit this week challenging federal marijuana rescheduling efforts.

The political coalition behind this lawsuit is worth paying attention to. It’s not prohibitionists arguing cannabis is dangerous. It’s a mix of medical professionals with genuine concerns about the research process and pharmaceutical interests who have financial stakes in keeping cannabis in a regulatory category they can control. Those are very different motivations dressed up in the same lawsuit.

What this tells me is that the opponents of reform have largely abandoned the public opinion battlefield — they’ve lost it — and are now fighting on administrative and legal terrain. That’s a slower game, but it can be effective. Federal administrative law is complicated, courts move slowly, and a successful legal challenge could delay rescheduling by years.

Operators should not assume rescheduling is a done deal. I’m not saying it fails — I think it eventually succeeds — but the path runs through federal courts now, not just agency rulemaking, and that adds meaningful uncertainty to the timeline.

The bottom line: The next major cannabis battles will be won and lost inside courtrooms. If you don’t have someone on your team who understands federal administrative law, you have a gap.

Wisconsin is the next big domino — and candidates know it.

Democratic gubernatorial candidates in Wisconsin pledged this week to support cannabis legalization, hemp protections, and additional executive actions if elected.

Wisconsin is one of the largest remaining states without adult-use legalization, and it sits surrounded by states that have moved. Illinois is generating over a billion dollars a year in cannabis tax revenue directly across the border. That’s not an abstract policy argument — that’s money Wisconsin is watching leave.

The political dynamics are shifting. When Republican-leaning rural voters start connecting cannabis legalization to farm income (hemp) and tax revenue (adult-use), the partisan math changes. Wisconsin is closer to moving than the headlines suggest.

The bottom line: Non-legalized states with legalized neighbors are running out of reasons to wait. Watch Wisconsin closely.

Share

California just complicated tribal cannabis — again.

California Attorney General Rob Bonta issued an opinion this week stating that tribes seeking to participate in statewide cannabis commerce must obtain state licenses — they cannot operate under tribal sovereignty alone.

This one is genuinely complicated, and I want to resist the urge to oversimplify it.

Tribal sovereignty is a serious legal principle with deep roots in federal law. The argument that tribes should be able to operate cannabis businesses outside state licensing frameworks isn’t frivolous — it’s grounded in legitimate legal theory. At the same time, California built its cannabis regulatory system on the premise that everyone operating in the state market plays by the same rules. Both of those things can be true simultaneously.

What this ruling really signals is that cannabis is now complex enough that it’s surfacing legal tensions that have existed for decades in other industries. The intersection of tribal law, federal law, and state cannabis regulation is going to generate litigation for years.

The bottom line: Jurisdictional and licensing complexity is only increasing. If your business touches multiple regulatory frameworks, you need counsel who understands all of them.

Republicans are fighting for hemp. That’s not a headline from five years ago.

Even after this week’s setbacks, Republican lawmakers are continuing to push for federal protections for the hemp-derived cannabinoid industry.

The political significance here shouldn’t be underestimated. Cannabis reform used to be a Democratic issue. Hemp protection is increasingly a Republican one — driven by agricultural districts, small business interests, and economic development concerns in rural states. That’s a genuine realignment.

When Republican legislators from conservative states are fighting to protect hemp THC products, the “cannabis is a liberal issue” framing is finished. This is now an economic issue with a broad bipartisan constituency, which means it will eventually get addressed by Congress — the question is just whether the result helps or hurts current operators.

The bottom line: The bipartisan coalition forming around hemp is the most underreported political development in cannabis right now. Pay attention to it.

Read more

It finally has it.

And somehow, that’s made everything more confusing.

We’ve entered what I’m calling the Clarification Era — and I’d argue it’s going to be harder to navigate than the prohibition era was.

At least under prohibition, the rules were clear: cannabis was illega…

Read more

Legalization.

Today, it faces a much harder one:

Institutionalization.

The latest developments in the cannabis space paint a picture of an industry entering a new phase—one where the biggest threats and opportunities are no longer coming from activists or ballot initiatives, but from:

• Federal regulators

• St…

Read more

It is now colliding directly with the center of it.

Over the last 24 hours, the latest reporting from the industry reveals an industry rapidly entering its most consequential phase yet:

the federal implementation era.

That means:

• lawsuits,

• administrative hearings,

• polling wars,

• lab…

Read more

Today, it’s being absorbed into it.

The latest developments from last few days reveal a rapidly evolving landscape where marijuana is no longer treated solely as:

• a cultural issue,

• a criminal issue,

• or even just a state-level issue.

Cannabis is now becoming:

• a healthcare issue,

• a labor iss…

Read more